Veloxis Pharmaceuticals A/S (VELOX.CO) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Wright Reports
$75.00
Provider : Reuters Investment Profile
$20.00
Provider : GlobalData
$300.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Veloxis Pharmaceuticals A/S maintains FY 2014 guidance


Wednesday, 20 Aug 2014 01:42pm EDT 

Veloxis Pharmaceuticals A/S:Maintains FY 2014 outlook with an operating loss of 60-90 million Danish crowns and a net loss of 55-85 million Danish crowns for FY 2014.FY 2014 EBIT of (89.00) million Danish crowns, net income of (85.00) million Danish crowns - Thomson Reuters I/B/E/S.